Literature DB >> 24758504

[Where does Ewing sarcoma end and begin - two cases of unusual bone tumors with t(20;22)(EWSR1-NFATc2) alteration].

Zdeněk Kinkor, Tomáš Vaneček, Marián Svajdler, Petr Mukenšnabl, Karel Veselý, Jan Baxa, Milan Kokavec.   

Abstract

The authors present two cases of Ewing-like sarcoma of the humerus and femur of a 12-year-old boy and a 28-year-old male, respectively. Identical morphology in both tumors consisted of multiple solid nests with a mosaic collection of small, round, uniform cells with clear cytoplasm and no apparent nuclear atypia. A monotonous structural arrangement, including both rich vascularity of bordering septae and significant admixtures of eosinophil leucocytes, resulted in a final organoid "neuroendocrine-like" pattern. Immunohistochemistry revealed diffuse strong CD10, CD99 and CD138 positivity. Detailed molecular analysis in both tumors confirmed translocation t(20;22) resulting in an EWSR1-NFATc2 fusion gene. Additionally, this translocation was accompanied by amplification of the proximal part of the genes and surrounding areas. Clinically, both neoplasms behaved aggressively and they were primarily chemoresistant. Four years later, the patient with the lesion in the humerus developed a massive local recurrence with a disruption of osteosynthesis. The last follow-up disclosed suspicious metastatic deposits in the lung. The boy with the femoral tumor underwent a total femoral prosthesis and there are no signs of local or systemic recurrence after 11 months of follow-up. The authors discuss the taxonomic placement of these rare examples of Ewing-like sarcoma family in the light of new molecular discoveries.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24758504

Source DB:  PubMed          Journal:  Cesk Patol        ISSN: 1210-7875


  5 in total

Review 1.  EWSR1/FUS-NFATc2 rearranged round cell sarcoma: clinicopathological series of 4 cases and literature review.

Authors:  Julio A Diaz-Perez; G Petur Nielsen; Cristina Antonescu; Martin S Taylor; Santiago A Lozano-Calderon; Andrew E Rosenberg
Journal:  Hum Pathol       Date:  2019-05-09       Impact factor: 3.466

2.  NKX3-1 Is a Useful Immunohistochemical Marker of EWSR1-NFATC2 Sarcoma and Mesenchymal Chondrosarcoma.

Authors:  Ken-Ichi Yoshida; Isidro Machado; Toru Motoi; Antonina Parafioriti; Maribel Lacambra; Hitoshi Ichikawa; Akira Kawai; Cristina R Antonescu; Akihiko Yoshida
Journal:  Am J Surg Pathol       Date:  2020-06       Impact factor: 6.394

3.  EWSR1-PATZ1-rearranged sarcoma: a report of nine cases of spindle and round cell neoplasms with predilection for thoracoabdominal soft tissues and frequent expression of neural and skeletal muscle markers.

Authors:  Michael Michal; Brian P Rubin; Abbas Agaimy; Kemal Kosemehmetoglu; Erin R Rudzinski; Konstantinos Linos; Ivy John; Zoran Gatalica; Jessica L Davis; Yajuan J Liu; Jesse K McKenney; Steven D Billings; Marián Švajdler; Olena Koshyk; Zdeněk Kinkor; Květoslava Michalová; Antonina V Kalmykova; Zarifa Yusifli; Nikola Ptáková; Veronika Hájková; Petr Grossman; Petr Šteiner; Michal Michal
Journal:  Mod Pathol       Date:  2020-10-04       Impact factor: 7.842

4.  NFATc2-rearranged sarcomas: clinicopathologic, molecular, and cytogenetic study of 7 cases with evidence of AGGRECAN as a novel diagnostic marker.

Authors:  Raul Perret; Julien Escuriol; Valérie Velasco; Laetitia Mayeur; Isabelle Soubeyran; Christophe Delfour; Sébastien Aubert; Marc Polivka; Marie Karanian; Alexandra Meurgey; Sophie Le Guellec; Noelle Weingertner; Sylvia Hoeller; Jean-Michel Coindre; Frédérique Larousserie; Gaëlle Pierron; Franck Tirode; François Le Loarer
Journal:  Mod Pathol       Date:  2020-04-23       Impact factor: 7.842

5.  Multiscale-omic assessment of EWSR1-NFATc2 fusion positive sarcomas identifies the mTOR pathway as a potential therapeutic target.

Authors:  Nathan D Seligson; Richard D Maradiaga; Colin M Stets; Howard M Katzenstein; Sherri Z Millis; Alan Rogers; John L Hays; James L Chen
Journal:  NPJ Precis Oncol       Date:  2021-05-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.